Antibody developer Xencor misses Q3 revenue estimates, net loss narrows

Xencor

05/11/2025 21:26

Overview

Xencor Q3 revenue of $21 mln missed analyst expectations

Net loss for Q3 reduced to $6 mln from $46.3 mln last year

Company advances clinical programs in oncology and autoimmune diseases

Outlook

Xencor expects to end 2025 with $570 mln to $590 mln in cash

Company plans pivotal studies for XmAb819 and XmAb541 in 2027

Xencor to start XmAb657 clinical studies by end of 2025

Result Drivers

REVENUE MISS - Q3 revenue rose to $21 mln primarily due to non-cash royalty revenue from Alexion and Incyte

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$21 mln
$27.15 mln (12 Analysts)
Q3 EPS
-$0.08
Q3 Net Income
-$6.03 mln
Q3 Operating Expenses
$68.52 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Xencor Inc is $27.00, about 49.3% above its November 4 closing price of $13.70

Press Release: ID:nBw6hvQHxa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)